BPG is committed to discovery and dissemination of knowledge
Articles in Press
8/14/2026 10:14:03 AM | Browse: 18 | Download: 3
| Category |
Immunology |
| Manuscript Type |
Minireviews |
| Article Title |
From virological selection to immune stratification: Hepatitis B virus-specific T cells for precision pegylated interferon therapy in chronic hepatitis B
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Bing Tian, Chen Tian, Chuan-Lai Shen and Qun Zhang |
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Jiangsu Province High-Level Hospital Construction Funds of Zhongda Hospital, School of Medicine, Southeast University |
2024GSPKY23 |
| Chinese Foundation for Hepatitis Prevention and Control Muxin research fund of CHB |
MX202413 |
|
| Corresponding Author |
Qun Zhang, MD, PhD, Department of Infectious Diseases, Zhongda Hospital, Southeast University, 87 Ding Jia Qiao, Nanjing 210009, Jiangsu Province, China. slim888@163.com |
| Key Words |
Chronic hepatitis B; Hepatitis B virus-specific T cells; Pegylated interferon; Functional cure; Immune stratification |
| Core Tip |
Currently, patient selection for pegylated interferon (PEG-IFN) therapy predominantly relies on virological markers, which fail to fully recapitulate host immune competence. This review highlights that hepatitis B virus-specific T cells constitute core immune biomarkers predictive of treatment response and functional cure. Synthesizing available evidence concerning T cell exhaustion, regenerative potential, effector function and comprehensive immune profiling, we propose that future patient selection algorithms should transition from virology-only criteria toward immune stratification strategies. This conceptual framework underpins the development of precision PEG-IFN therapy for chronic hepatitis B. |
| Citation |
Tian B, Tian C, Shen CL, Zhang Q. From virological selection to immune stratification: Hepatitis B virus-specific T cells for precision pegylated interferon therapy in chronic hepatitis B. World J Hepatol 2026; In press
|
| PDF |
124884-in-press.pdf
|
 |
Received |
|
2026-07-01 00:13 |
 |
Peer-Review Started |
|
2026-07-01 00:13 |
 |
First Decision by Editorial Office Director |
|
|
 |
Return for Revision |
|
2026-07-22 05:52 |
 |
Revised |
|
2026-07-31 12:25 |
 |
Publication Fee Transferred |
|
|
 |
Second Decision by Editor |
|
2026-08-13 02:29 |
 |
Second Decision by Editor-in-Chief |
|
|
 |
Final Decision by Editorial Office Director |
|
2026-08-14 10:14 |
 |
Articles in Press |
|
2026-08-14 10:14 |
 |
Edit the Manuscript by Language Editor |
|
|
 |
Typeset the Manuscript |
|
|
| ISSN |
1948-5182 (online) |
| Open Access |
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc. |
| Copyright |
©Author(s) (or their employer(s)) 2026. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc. |
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.